MENU

BEAM Stock Beam Therapeutics (BEAM, $17.22) entered Downtrend as Momentum indicator drops below 0 level on May 22, 2025

A.I.dvisor
at Tickeron.com
Loading...
BEAM - Beam Therapeutics
Momentum signal
Bearish Trend
Odds of DOWN Trend
Tickeron
Momentum signal
Price: $17.22
Daily change: $0 (0%)
Daily volume: 2.7K
Capitalization: $1.7B
Industry: Biotechnology
This indicator may be signaling that BEAM's price has further to drop, since it fell below its price logged 14 days ago. Traders may consider selling the stock, shorting the stock, or exploring put options. A.I.dvisor backtested 93 similar cases where BEAM's Momentum Indicator fell below the 0 level, and of them led to a successful outcome. Odds of Success:

Momentum Indicator for BEAM turns negative, indicating new downward trend

BEAM saw its Momentum Indicator move below the 0 level on May 22, 2025. This is an indication that the stock could be shifting in to a new downward move. Traders may want to consider selling the stock or exploring put options. Tickeron's A.I.dvisor looked at 93 similar instances where the indicator turned negative. In of the 93 cases, the stock moved further down in the following days. The odds of a decline are at .

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

Following a 3-day decline, the stock is projected to fall further. Considering past instances where BEAM declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

Bullish Trend Analysis

The Stochastic Oscillator is in the oversold zone. Keep an eye out for a move up in the foreseeable future.

The Moving Average Convergence Divergence (MACD) for BEAM just turned positive on May 12, 2025. Looking at past instances where BEAM's MACD turned positive, the stock continued to rise in of 53 cases over the following month. The odds of a continued upward trend are .

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where BEAM advanced for three days, in of 295 cases, the price rose further within the following month. The odds of a continued upward trend are .

BEAM may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

The Aroon Indicator entered an Uptrend today. In of 177 cases where BEAM Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.507) is normal, around the industry mean (16.345). P/E Ratio (0.000) is within average values for comparable stocks, (59.117). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (2.182). Dividend Yield (0.000) settles around the average of (0.024) among similar stocks. P/S Ratio (22.222) is also within normal values, averaging (279.466).

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating slightly better than average sales and a considerably profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating slightly worse than average price growth. BEAM’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. BEAM’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.

View a ticker or compare two or three
BEAM
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interact to see
Advertisement
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

a company, which develops and commercializes DNA base editing technologies for the treatment of human disease.

Industry Biotechnology

Profile
Fundamentals
Details
Industry
N/A
Address
238 Main Street
Phone
+1 857 327-8775
Employees
436
Web
https://www.beamtx.com